Key result
Bidirectional VT is linked to a ~47% rate of death or recurrence.
Why the study?
Survival, therapeutic approaches, and clinical prognosis following bidirectional ventricular tachycardia (BiVT) were unknown.
Cohort (n=19)
Yes
In the largest structured follow-up cohort of bidirectional ventricular tachycardia to date, nearly half of patients experienced recurrence or death, with outcomes driven by underlying etiology (high recurrence in channelopathies and mortality restricted to structural heart disease) rather than the ECG pattern itself.
Answers are grounded in this paper and cite their sources.
BiVT registry data in 19 patients remain hypothesis-generating; leaves open optimal management and prognosis in larger cohorts.
Background Survival and clinical prognosis after bidirectional ventricular tachycardia (BiVT), defined as a dual QRS morphologies alternating on a beat-to-beat basis in the inferior leads, is unknown. Purpose To describe events during follow-up and therapeutic approaches to BiVT. Methods We conducted an ambispective and multicentric registry on 13 hospitals, consisting on relevant clinical characteristics, diagnosis, therapeutics and follow-up. Results A total of 19 patients were evaluated, with their clinical characteristics and etiologies summarized in the Table. Among them, 42% received an implantable cardioverter-defibrillator (ICD) before discharge. The mean follow-up period was 39 (12;104) months. Beta-blockers were the most commonly prescribed and clinically effective medication at discharge (26.32%), followed by flecainide and amiodarone. The recurrence rate during follow-up was 36.84%. No in-hospital mortality was observed; however, two patients died within the first year after the event, due to heart failure and septic shock. Kaplan-Meier curves (Figure) illustrate the composite endpoint of death and/or recurrences (n=9). Distinct etiologies showed varying recurrence rates (n=7), with channelopathies (Andersen-Tawil and/or CPVT) accounting for the highest recurrence rate at 71% (5 cases). In contrast, all mortality events occurred in patients with structural heart disease. Conclusion Our study represents the largest population of BiVT described to date with structured follow-up. Both, recurrences and mortality are linked to the etiology rather than the descriptive bidirectionality on the ECG. Nearly half of the population suffered the composite end-point of recurrence and/or death, which might be due to the existence of a permanent trigger (i.e. channelopathy) and the absence of etiology-tailored treatments.
No takes yet. Share an insight, caveat, or question.
Vazirani et al. (2025) conducted a cohort in Bidirectional ventricular tachycardia (BiVT) (n=19). Bidirectional ventricular tachycardia (BiVT) management (ICD implantation, beta-blockers, flecainide, amiodarone) was evaluated on Composite endpoint of death and/or recurrences. Bidirectional ventricular tachycardia was associated with a 36.84% recurrence rate and a 47.4% (9/19) rate of the composite endpoint of death and/or recurrence over a mean 39-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: